DOCSLIB.ORG

Genetic Testing and Common Disorders in a Public Health Framework: How to Assess Relevance and Possibilities

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Genetic Testing and Common Disorders in a Public Health Framework: How to Assess Relevance and Possibilities European Journal of Human Genetics (2011) 19, S6–S44 & 2011 Macmillan Publishers Limited All rights reserved 1018-4813/11 www.nature.com/ejhg POLICY Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities Background Document to the ESHG recommendations on genetic testing and common disorders Frauke Becker1,26, Carla G van El2,26, Dolores Ibarreta3, Eleni Zika3, Stuart Hogarth4, Pascal Borry2,5,6, Anne Cambon-Thomsen7, Jean Jacques Cassiman8, Gerry Evers-Kiebooms9, Shirley Hodgson10, ACe´cile JW Janssens11, Helena Kaariainen12, Michael Krawczak13, Ulf Kristoffersson14, Jan Lubinski15, Christine Patch16, Victor B Penchaszadeh17, Andrew Read18, Wolf Rogowski19,20, Jorge Sequeiros21, Lisbeth Tranebjaerg22, Irene M van Langen23, Helen Wallace24, Ron Zimmern25,Jo¨rg Schmidtke1 and Martina C Cornel*,2 European Journal of Human Genetics (2011) 19, S6–S44; doi:10.1038/ejhg.2010.249 Keywords: common disorders; genetic testing; predictive value; monogenic subtypes; public health INTRODUCTION environment interactions. We will use the term ‘complex disease’ Background and purpose to indicate diseases with variable etiology, including multifactorial During the years prior to the turn of the century, scientific and etiology as well as monogenic subsets. When discussing ‘susceptibility medical attention for genetic disorders was mainly focused on under- genes’ in this document, we refer to genetic variants with low standing rare single-gene disorders, such as Huntington’s disease, predictive value. We need to admit, however, that no generally Duchenne muscular dystrophy, and cystic fibrosis (CF), as well as accepted threshold for categorizing predictive value levels exists. chromosomal abnormalities. The medical specialty of clinical genetics Researchers nowadays study the myriad of genetic polymorphisms was established in the 1980s and 1990s in many European countries to that have been identified during and since the Human Genome diagnose these kinds of rare disorders and to counsel patients and Project. The spectacular growth of genome-wide association studies1 families. has shed new light on which of these variants represent risk factors for In recent years, the attention of the genomics and genetics research common diseases. Understanding the pathogenesis and etiology, and community has shifted toward understanding the basis of common finding new ways to prevent and treat those diseases are major complex disorders. Common diseases are diseases frequently encoun- challenges. The traits or diseases under study include coronary artery tered in health care. Some cases of common disorders are character- disease, myocardial infarction, stroke, peripheral artery disease, obe- ized by a strong influence of germline mutations in a single gene; these sity, type 1 diabetes, type 2 diabetes, breast cancer, cervical cancer, will be referred to as ‘monogenic subtypes’. In many cases common colorectal cancer, prostate cancer, celiac disease, bipolar disorder, disorders have a multifactorial etiology: they are caused by several Crohn’s disease, and many more. Should incorporation of these genes and environmental factors, involving gene–gene and/or gene– research results into current clinical and public health practice become 1Hannover Medical School, Department of Human Genetics, Hannover, Germany; 2Department of Clinical Genetics and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands; 3IPTS Institute for Prospective Technological Studies, Joint Research Centre, European Commission, Seville, Spain; 4Department of Social Sciences, Loughborough University, Loughborough, UK; 5Centre for Biomedical Ethics and Law, Katholieke Universiteit Leuven, Leuven, Belgium; 6Department of Medical Humanities and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, The Netherlands; 7Inserm, U 558, Department of Epidemiology, Health Economics and Public Health, University Paul Sabatier, Toulouse, France; 8Center for Human Genetics, University of Leuven, Leuven, Belgium; 9Psychosocial Genetics Unit University Hospitals, Katholieke Universiteit Leuven, Leuven, Belgium; 10Department of Clinical Genetics, St George’s University of London, London, UK; 11Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam, The Netherlands; 12National Institute for Health and Welfare, Helsinki, Finland; 13Institute of Medical Informatics and Statistics, Christian-Albrechts-Universita¨t, Kiel, Germany; 14Department of Clinical Genetics, University Hospital, Lund, Sweden; 15Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland; 16Guys and St Thomas’ NHS Foundation Trust, London, UK; 17Mailman School of Public Health, Columbia University, New York, NY, USA; 18Division of Human Development, School of Clinical Sciences, University of Nottingham, Nottingham, UK; 19Helmholtz Center Munich, German Research Center for Environmental Health (GmbH), Neuherberg, Germany; 20Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Clinical Center, Ludwig Maximilians University, Munich, Germany; 21IBMC – Institute for Molecular and Cell Biology, and ICBAS, University of Porto, Porto, Portugal; 22Department of Audiology, H:S Bispebjerg Hospital and Wilhelm Johannsen Centre of Functional Genomics, University of Copenhagen, Copenhagen, Denmark; 23Department of Genetics, University Medical Center Groningen and University of Groningen, Groningen, The Netherlands; 24GeneWatch UK, The Mill House, Tideswell, Derbyshire, UK; 25PHG Foundation, Worts Causeway, Cambridge, UK *Correspondence: Professor MC Cornel, Department of Clinical Genetics and EMGO Institute for Health and Care Research, VU University Medical Center, BS7, D423, PO Box 7057, 1007 MB Amsterdam, The Netherlands. Tel: +31 20 4448910; Fax: +31 20 4448181; E-mail: [email protected] 26These authors contributed equally to this work. ESHG background document genetic testing and common disorders FBeckeret al S7 possible, then researchers and practitioners have to be prepared for the services and at improving the overall quality of genetic services offered way in which this changes their daily routine.2–8 within the EU. This includes both the establishment of procedures and The clinical management of information about frequently occurring guidelines for the validation of methods and technologies and DNA variants that lead to moderate increases in risks for common the provision of quality-assured information sources to medical diseases requires a different approach from that of the significantly professionals, as well as proper utilization of genetic services. The increased genetic risks for numerous rare health problems. Translation IPTS is one of the seven scientific institutes of the European Commis- of research findings to useful health-care applications appears to be sion’s Joint Research Centre (JRC). It informs EU policy making on lagging behind. Implementation of useful research findings may take issues with a socioeconomic and a scientific or technological dimension. years or decades. Meanwhile, some applications of very limited clinical After the Seville workshop, to enable further discussion on some utility have become available directly to the consumers. Difficulties genetic epidemiological issues, a workshop was organized in Septem- with the translation of research findings need to be understood and ber 2008 in Amsterdam. The background document was revised into addressed if genetics and genomics research is to fulfil its promises its present form on the basis of comments by participants of both towards improving diagnosis, treatment, and prevention. Currently meetings and other experts, some of whom are active in the EU- (in 2010) the genetics research community is skeptical about the funded Public Health Genomic European Network (PHGEN, http:// possibilities of genetic susceptibility testing and screening contributing www.phgen.eu) project and the international GRAPH-Int (http:// significantly to the improvement of the quality of health care. The www.graphint.org) consortium that was established under the Cana- implementation in health care of genetic tests that are considered dian Public Health Agency. These organizations have been established useful should overcome several thresholds. to promote, at both the European and the global level, responsible and Health promotion and disease prevention for the population at effective translation of genome-based knowledge and technologies large has been the domain of public health professionals; yet, public into public policy and public health services. health approaches have thus far not taken into account genetic risk Suggestions were incorporated in the background document, and factors and often not even family history.9 So far, advice on lifestyle, during the process the PPPC discussed the recommendations. A draft physical activity, and nutrition has been developed in a one-size-fits- of the background document and recommendations were distributed all approach.6 The era of genomics presents the promise of persona- and posted on the web during the summer of 2009 to elicit further lized prevention and drug treatment, which has been met with comments. After this procedure the draft was revised. The PPPC and enthusiasm by many people, but called into question by others.10 the Board of the ESHG approved the final version. This final text is In the light of these
Load more

Recommended publications
  • An Introduction to the CDC Public Health Genomics Knowledge Base
    Division of Public Health Information Dissemination Center for Surveillance, Epidemiology, and Laboratory Services An Introduction to the CDC Public Health Genomics Knowledge Base Marta Gwinn, Dave Dotson, Wei Yu & Ridgely Fisk Green Office of Public Health Genomics Division of Public Health Information Dissemination CDC Office of Public Health Genomics (OPHG) Effective and responsible translation of genome-based discoveries into disease prevention and population health https://www.cdc.gov/genomics 1. Identify 2. Inform 3. Integrate evidence-based applications and communicate into practice & programs OPHG, DPHID, CSELS CDC Information Database Why did we build it? . Challenge: Finding information about genomics- and family health history-related activities at CDC . Opportunity: Provide a centralized, searchable, publicly available database for CDC resources related to genomics and family health history CDC-Authored Genomics Publications Database Why did we build it? . Challenge: Finding CDC-authored publications on genomics and family health history . Opportunity: Provide a centralized, searchable, publicly available database for these CDC publications . Challenge: CDC’s work in genomics and family health history is not well known . Opportunity: Showcase CDC publications to highlight work related to genomics and family health history CDC-Authored Genomic Publications Database continued . Scientific articles and reports with at least one CDC author . CDC Science Clips: https://www.cdc.gov/library/sciclips/ . PubMed . Scopus affiliation search . Author notifications Genomics and Health Impact Scan Database Why did we build it? . Challenge: Keeping up with the latest developments in genomics and family health history relevant to public health . Opportunity: Identify the latest publications and other resources on population-based applications of genomic discoveries .
    [Show full text]
  • The Patentability of Synthetic Organisms
    Creating Life from Scratch: The Patentability of Synthetic Organisms Michael Saunders* I. INTRODUCTION ................................................................................... 75 II. PATENTING MICROBIAL LIFE—CHAKRABARTY ................................ 77 III. PATENTING MULTICELLULAR LIFE—HARVARD ONCOMOUSE .......... 80 IV. IMPLICATIONS FOR SYNTHETIC BIOLOGY .......................................... 83 A. Single-Celled Synthetic Organisms ......................................... 83 B. Multicellular Synthetic Organisms .......................................... 86 V. CONCLUSIONS ..................................................................................... 88 I. INTRODUCTION Published in May 2007, U.S. application no. 20070122826 (Venter patent) describes a minimally operative genome of the bacterium Mycoplasma genitalium consisting of 381 genes, which the inventors believe to be essential for the survival of the bacterium in an environment containing all the necessary nutrients and free from stress.1 However, the team of inventors from the J. Craig Venter Institute is trying to accomplish something more than just the usual patenting of genes; they intend to create and patent the world’s first artificial organism. The team has already cleared two of the three major hurdles on its way to constructing this first synthetic organism. In January 2008, they announced completion of the second step, the laboratory synthesis of the entire 582,970 base pairs of the genome described in the patent above.2 What remains is the third and final step of inserting this human-made genome into a bacterial cell chassis and “booting up” the organism.3 Craig Venter and Hamilton Smith, lead researchers on the team have been discussing the creation of synthetic life since 1995, when their team published the first complete genome sequence of a living * © 2008 Michael Saunders. J.D. candidate 2009, Tulane University School of Law; B.S. 2003, Bucknell University. 1.
    [Show full text]
  • 10 Harvard Mouse
    The Harvard Mouse or the transgenetic technique Term Paper Biology Georgina Cibula, 4e LIST of Contents Preface What is my motivation to work on the chosen topic? What is especially interesting? What are our questions with respects to the chosen topic? Introduction What is the context of the chosen topic? What is the recent scientific history? Where and why is the technique used? Are there alternatice treatments? Description of engineering technique No institution visited Discussion What progress was made with the application of the chosen technique? What future research steps? Ethical aspects Summary References PREFACE What is my motivation to work on the chosen topic? There are many reasons. One of them is that it’s a very interesting topic. It is fascinating, how you can increase or decrease the functionality of organisms. What is especially interesting? The intricacy. And that you can use the method not only for mice but for every organism. For example in the Green genetic engineering (to make plants more resistant) or for pharmaceuticals like human insulin. Some genes are responsible for the aging process. So if we can find those genes and deactivate them we would life longer. First successful experiments with animals where already made. What I also like about this topic is the big ethic question behind it. I mean in the end we use animals, often mice because of their similarity to our genes, to benefit of them. We intentional make them ill and lock them into small cages. But on the other hands medicaments can be tested or invented which can save many human lifes.
    [Show full text]
  • View Eposter
    Combined glucocorticoid and mineralocorticoid deficiency related to a new NNT mutation : a case report E.Doye 1, CL.Gay 1, S.Castets 1, F.Roucher-Boulez 2, Y.Morel 2, I.Plotton 2, M.Nicolino 1 1 CHU Hospices Civils de Lyon, Service d’Endocrinologie Pédiatrique, Lyon, France ; 2 Hospices Civils de Lyon, Laboratoire d’Endocrinologie Moléculaire et Maladies Rares, Lyon, France BACKGROUND OBJECTIVE Familial glucocorticoid deficiency is an autosomal recessive disorder To describe a new case of familial characterized by specific failure of adrenocortical glucocorticoid glucocorticoid deficiency with combined production in response to adrenocorticotropic hormone (ACTH). mineralocorticoid insufficiency and extra Mutations of the NNT (nicotinamide nucleotide transhydrogenase) adrenal manifestations. gene have recently been implicated in familial glucocorticoid deficiency. RESULTS Suffering from a febrile viral respiratory Diagnosis : during At one month At six months disease, an eight-month-old boy presented hypoglycémia and with status epilepticus caused by severe hypotension hypoglycemia. Multiple medical complications occurred, and invasive ventilation was Natremia (mmol/L) 135 126 136 required for 18 days. The results of blood tests performed during hypoglycemia revealed ACTH (ng/L) 1382 >2000 >2000 adrenal insufficiency. Renin and aldosterone Cortisol (nmol/L) <20 - <20 levels were high but considered consistent Renin (ng/L) 2880 278 177 with the mild hyponatremia and severe hypotension. Subsequent measurements Aldosterone (pmol/L) - 179 72
    [Show full text]
  • NNT Mutations: a Cause of Primary Adrenal Insufficiency, Oxidative Stress and Extra- Adrenal Defects
    175:1 F Roucher-Boulez and others NNT, adrenal and extra-adrenal 175:1 73–84 Clinical Study defects NNT mutations: a cause of primary adrenal insufficiency, oxidative stress and extra- adrenal defects Florence Roucher-Boulez1,2, Delphine Mallet-Motak1, Dinane Samara-Boustani3, Houweyda Jilani1, Asmahane Ladjouze4, Pierre-François Souchon5, Dominique Simon6, Sylvie Nivot7, Claudine Heinrichs8, Maryline Ronze9, Xavier Bertagna10, Laure Groisne11, Bruno Leheup12, Catherine Naud-Saudreau13, Gilles Blondin13, Christine Lefevre14, Laetitia Lemarchand15 and Yves Morel1,2 1Molecular Endocrinology and Rare Diseases, Lyon University Hospital, Bron, France, 2Claude Bernard Lyon 1 University, Lyon, France, 3Pediatric Endocrinology, Gynecology and Diabetology, Necker University Hospital, Paris, France, 4Pediatric Department, Bab El Oued University Hospital, Alger, Algeria, 5Pediatric Endocrinology and Diabetology, American Memorial Hospital, Reims, France, 6Pediatric Endocrinology, Robert Debré Hospital, Paris, France, 7Department of Pediatrics, Rennes Teaching Hospital, Rennes, France, 8Pediatric Endocrinology, Queen Fabiola Children’s University Hospital, Brussels, Belgium, 9Endocrinology Department, L.-Hussel Hospital, Vienne, France, 10Endocrinology Department, Cochin University Hospital, Paris, France, 11Endocrinology Department, Lyon University Hospital, Bron-Lyon, France, 12Paediatric and Clinical Genetic Department, Correspondence Nancy University Hospital, Vandoeuvre les Nancy, France, 13Pediatric Endocrinology and Diabetology, should be
    [Show full text]
  • University-Industry Partnerships and the Licensing of the Harvard Mouse
    PATENTS Managing innovation: university-industry partnerships and the licensing of the Harvard mouse Sasha Blaug1,Colleen Chien1 & Michael J Shuster DuPont’s Oncomouse patent licensing program continues to cause a stir in academia and industry. ver the last several decades, technology restructuring in the 1980s resulting in optimized for mutual near- and long-term Oand technological innovation have reduced industry R&D spending and scarcer benefits to the parties? Recently this dialog gradually replaced manufacturing and agri- federal R&D funding. Increased technology has been focused on DuPont’s licensing of culture as the main drivers of the US econ- transfer has sparked a debate on univ- the transgenic ‘Harvard mouse,’ subse- omy. The unparalleled system of American ersities’ roles in the national economy: on quently trademarked as the Oncomouse6. research universities1 and their association the extent to which these relationships affect http://www.nature.com/naturebiotechnology with industry are important drivers of the the mission of universities to carry out The Oncomouse patents new economy. The relationship between and disseminate the results of basic DuPont’s patent licensing program for universities and industry is multifaceted, research, and on how universities can man- ‘Oncomouse technology’ has caused a stir in encompassing exchanges of knowledge, age their partnerships, collaborations and academia and industry for over a decade7. expertise, working culture and money. technology transfer without compromising These patents broadly claim transgenic Whereas the transfer of technology from their mission. nonhuman mammals expressing cancer- universities to industry has been going on In the basic research paradigm, inves- promoting oncogenes, a basic research tool for more than a century, ties between uni- tigators’ inquiries are directed toward dev- widely used in the fight against cancer.
    [Show full text]
  • Waterkwaliteitsopgave 2016-2021 Uitwerking Voor De Waterlichamen
    Waterkwaliteitsopgave 2016-2021 Uitwerking voor de waterlichamen Factsheets, september 2015 1 Inhoudsopgave Stroomgebieden Waterschap Rijn en IJssel ................................................................................................. 2 Stroomgebied Schipbeek ............................................................................................................................. 3 Buurserbeek ................................................................................................................................................. 4 Dortherbeek ................................................................................................................................................. 7 Dortherbeek-Oost......................................................................................................................................... 9 Elsbeek (Nieuwe waterleiding) ................................................................................................................... 12 Oude Schipbeek .......................................................................................................................................... 14 Schipbeek.................................................................................................................................................... 16 Zoddebeek .................................................................................................................................................. 19 Zuidelijk afwateringskanaal .......................................................................................................................
    [Show full text]
  • International Social Security Review
    4.3 VOLUME | NUMBER 72 2 | APRIL– JUNE |2019 VOLUME 72 | NUMBER 2 www.issa.int APRIL–JUNE 2019 The International Social Security Association (ISSA) is the world’s leading international organization bringing together national social security administrations and agencies. The ISSA provides information, research, expert advice and platforms for members to build and promote dynamic social security systems and policy worldwide. International 2 | 2019 Social Security Review International Social Security Review Social International Second-pillar pensions in Central and Eastern Europe: Payment constraints and exit options Effective retirement age from employment and full-time employment, and the impact of the 2008 crisis How fair are unemployment benefits? The experience of East Asia Employer-oriented labour market policies in Sweden: Creating jobs and the division of labour in the public sector Social health protection in Cambodia: Challenges of policy design and implementation View this journal online at wileyonlinelibrary.com/journal/issr INTERNATIONAL SOCIAL SECURITY ASSOCIATION ASSOCIATION INTERNATIONALE DE LA SÉCURITÉ SOCIALE ASOCIACIÓN INTERNACIONAL DE LA SEGURIDAD SOCIAL INTERNATIONALE VEREINIGUNG FÜR SOZIALE SICHERHEIT Editorial Board First published in 1948, the International Social Security Review is the world’s major international quarterly pub- Chairperson Julien Damon, Sciences Po, Paris, Ecole nationale supérieure de sécurité sociale, France lication in the field of social security. Articles by leading academics and social security experts around the world Vice Chairperson Wouter van Ginneken, Independent Consultant, Geneva, Switzerland present international comparisons and in-depth discussions of topical questions as well as studies of social security Members Willem Adema, Organisation for Economic Co-operation and Development, Paris, France systems in different countries, and there are regular reviews of the latest publications in its field.
    [Show full text]
  • UC Irvine UC Irvine Previously Published Works
    UC Irvine UC Irvine Previously Published Works Title The C57BL/6J Mouse Strain Background Modifies the Effect of a Mutation in Bcl2l2 Permalink https://escholarship.org/uc/item/5152r99k Journal G3-Genes|Genomes|Genetics, 2(1) ISSN 2160-1836 Authors Navarro, S. J Trinh, T. Lucas, C. A et al. Publication Date 2012-01-06 DOI 10.1534/g3.111.000778 License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California INVESTIGATION The C57BL/6J Mouse Strain Background Modifies the Effect of a Mutation in Bcl2l2 Stefanie J. Navarro, Tuyen Trinh, Charlotte A. Lucas, Andrea J. Ross, Katrina G. Waymire, and Grant R. MacGregor1 Department of Developmental and Cell Biology, School of Biological Sciences, and Center for Molecular and Mitochondrial Medicine and Genetics, University of California Irvine, Irvine, California 92697-2300 ABSTRACT Bcl2l2 encodes BCL-W, an antiapoptotic member of the BCL-2 family of proteins. Intercross of KEYWORDS Bcl2l2 +/2 mice on a mixed C57BL/6J, 129S5 background produces Bcl2l2 2/2 animals with the expected –Nnt frequency. In contrast, intercross of Bcl2l2 +/2 mice on a congenic C57BL/6J background produces rela- mutation, genetic tively few live-born Bcl2l2 2/2 animals. Genetic modifiers alter the effect of a mutation. C57BL/6J mice modifier, BCL-W, (Mus musculus) have a mutant allele of nicotinamide nucleotide transhydrogenase (Nnt) that can act as apoptosis a modifier. Loss of NNT decreases the concentration of reduced nicotinamide adenine dinucleotide phos- phate within the mitochondrial matrix. Nicotinamide adenine dinucleotide phosphate is a cofactor for glutathione reductase, which regenerates reduced glutathione, an important antioxidant.
    [Show full text]
  • Guide to Biotechnology 2008
    guide to biotechnology 2008 research & development health bioethics innovate industrial & environmental food & agriculture biodefense Biotechnology Industry Organization 1201 Maryland Avenue, SW imagine Suite 900 Washington, DC 20024 intellectual property 202.962.9200 (phone) 202.488.6301 (fax) bio.org inform bio.org The Guide to Biotechnology is compiled by the Biotechnology Industry Organization (BIO) Editors Roxanna Guilford-Blake Debbie Strickland Contributors BIO Staff table of Contents Biotechnology: A Collection of Technologies 1 Regenerative Medicine ................................................. 36 What Is Biotechnology? .................................................. 1 Vaccines ....................................................................... 37 Cells and Biological Molecules ........................................ 1 Plant-Made Pharmaceuticals ........................................ 37 Therapeutic Development Overview .............................. 38 Biotechnology Industry Facts 2 Market Capitalization, 1994–2006 .................................. 3 Agricultural Production Applications 41 U.S. Biotech Industry Statistics: 1995–2006 ................... 3 Crop Biotechnology ...................................................... 41 U.S. Public Companies by Region, 2006 ........................ 4 Forest Biotechnology .................................................... 44 Total Financing, 1998–2007 (in billions of U.S. dollars) .... 4 Animal Biotechnology ................................................... 45 Biotech
    [Show full text]
  • NNT Is a Key Regulator of Adrenal Redox Homeostasis and Steroidogenesis in Male Mice
    236 1 Journal of E Meimaridou et al. NNT is key for adrenal redox 236:1 13–28 Endocrinology and steroid control RESEARCH NNT is a key regulator of adrenal redox homeostasis and steroidogenesis in male mice E Meimaridou1,*, M Goldsworthy2, V Chortis3,4, E Fragouli1, P A Foster3,4, W Arlt3,4, R Cox2 and L A Metherell1 1Centre for Endocrinology, William Harvey Research Institute, John Vane Science Centre, Queen Mary, University of London, London, UK 2MRC Harwell Institute, Genetics of Type 2 Diabetes, Mammalian Genetics Unit, Oxfordshire, UK 3Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK 4Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UK *(E Meimaridou is now at School of Human Sciences, London Metropolitan University, London, UK) Correspondence should be addressed to E Meimaridou: [email protected] Abstract Nicotinamide nucleotide transhydrogenase, NNT, is a ubiquitous protein of the Key Words inner mitochondrial membrane with a key role in mitochondrial redox balance. NNT f RNA sequencing produces high concentrations of NADPH for detoxification of reactive oxygen species f nicotinamide nucleotide by glutathione and thioredoxin pathways. In humans, NNT dysfunction leads to an transhydrogenase adrenal-specific disorder, glucocorticoid deficiency. Certain substrains of C57BL/6 mice f redox homeostasis contain a spontaneously occurring inactivating Nnt mutation and display glucocorticoid f steroidogenesis Endocrinology deficiency along with glucose intolerance and reduced insulin secretion. To understand f ROS scavengers of the underlying mechanism(s) behind the glucocorticoid deficiency, we performed comprehensive RNA-seq on adrenals from wild-type (C57BL/6N), mutant (C57BL/6J) Journal and BAC transgenic mice overexpressing Nnt (C57BL/6JBAC).
    [Show full text]
  • Systeembeschrijving Beheersgebied Oude Ijssel Juli 2016
    Systeembeschrijving Beheersgebied Oude IJssel juli 2016 Systeembeschrijving beheersgebied Oude IJssel Inhoud Introductie in de systeembeschrijvingen ................................................................................................ 3 1 Samenvatting Beheersgebied Oude IJssel ....................................................................................... 4 2 Algemene informatie ....................................................................................................................... 9 2.1 Gebiedsbegrenzing en indeling ............................................................................................... 9 2.2 Bodem en ondergrond .......................................................................................................... 10 2.3 Historie .................................................................................................................................. 15 2.4 Landschap en landgebruik ..................................................................................................... 19 2.5 Natuur.................................................................................................................................... 21 3 Watersysteem ............................................................................................................................... 24 3.1 Algemeen: Beheersgebied Oude IJssel .................................................................................. 24 3.2 Oude IJssel en Aastrang ........................................................................................................
    [Show full text]